Drug intelligence / Profile preview

Ascendant-221

Development stage: Unknown
Lead developer: Ascendant Health Sciences
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

Ascendant-221 is a Phase 2 clinical-stage anti-IgE monoclonal antibody being developed for the treatment of allergic diseases, including food allergy. Originally developed by Ascendant Health Sciences Ltd., the drug was licensed to Cue Biopharma in April 2026 for global development and commercialization (excluding mainland China, Hong Kong, Macau, and Taiwan). Ascendant-221 is described as a dual-mechanism anti-IgE antibody that targets immunoglobulin E (IgE). It is currently undergoing a Phase 2 study in China, with results expected in the second half of 2026, and plans are in place to initiate a global Phase 2b trial in food allergy following review of the China study data.

Targets

FCER2 (Low affinity immunoglobulin epsilon fc receptor)IgE (Immunoglobulin E)

Beyond the preview

Go deeper on Ascendant-221.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ascendant-221.

Explore the full profile